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ABSTRACT: Combination inhalers containing corticosteroids and long-acting b-agonists are used
to reduce exacerbation rates in patients with severe chronic obstructive pulmonary disease (COPD).
The FORWARD (Foster 48-week Trial to Reduce Exacerbations in COPD) clinical trial in severe
COPD patients is a comparison of extrafine beclomethasone dipropionate and formoterol in a
combination inhaler with extrafine formoterol; the co-primary end-points are exacerbation rates
over 48 weeks and improvement in forced expiratory volume in 1 s over 12 weeks. The traditional
physician diagnosis of exacerbations is a co-primary outcome, and the Exacerbations of Chronic
Pulmonary Disease Tool (EXACT) means of collecting patient-reported outcome data are also
being used to enhance the detection of exacerbation events. EXACT data are being collected
using a novel application of a digital platform technology.
FORWARD is therefore expected to provide information on the ability of EXACT to detect and
measure exacerbations in a large clinical trial setting. The study design of FORWARD is described
in this article.
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C
hronic obstructive pulmonary disease
(COPD) is a progressive condition char-
acterised by airway inflammation and
persistent airflow limitation. COPD patients often
experience exacerbations, which are an acute
worsening of symptoms beyond the normal day-
to-day variation [1]. Exacerbations of COPD,
which are associated with a worse quality of life
[2] and increased mortality [3], are more frequent
during the winter season [4, 5], being associated
with an increased prevalence of infections with
respiratory viruses [6]. These winter exacerbations
have a greater impact on patients in terms of
hospitalisations and recovery [5]. Recent work has
described a subgroup of COPD patients who are
susceptible to frequent exacerbations and that a
prior history of exacerbations predicts the future
risk of exacerbations [7].
An exacerbation is usually an event diagnosed by a
physician after the patient has reported increased
symptoms/signs. However, many exacerbations
are not reported by patients [2]. In clinical trials,
this under-reporting leads to an under-estimate of
exacerbation frequency [8]. Patient diaries can
improve the standardisation of symptom collection
and reduce the number of unreported events. The
Exacerbations of Chronic Pulmonary Disease Tool
(EXACT) is a recently developed means of collect-
ing patient-reported outcome (PRO) data, which
helps to capture not only the frequency of exacer-
bations but also the severity and the time-course, i.e.
onset, duration and recovery [9, 10]. This tool was
developed and validated specifically to meet the
standards required for PRO measurements in
clinical trials. In an observational study, EXACT
provided reproducible measurements in the stable
state and was sensitive to changes in symptoms
during exacerbations [11].
Long acting b-agonists (LABAs) are bronchodila-
tors that are used to control symptoms in COPD
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patients [12]. The addition of inhaled corticosteroids (ICS) to
LABAs is recommended in severe COPD patients with frequent
exacerbations [12]. Single combination inhalers are frequently
used to deliver ICS/LABA combinations, as this is a practical
approach for patients, which enhances the possibility of
synergistic interactions between the drugs after co-deposition
in the airways [13]. Single combination inhalers containing
fluticasone propionate/salmeterol (FP/S) and budesonide/
formoterol (BUD/F) are licensed for use in COPD patients, as
they both improve lung function and reduce exacerbation rates
compared with the LABA component alone [14–16].
An ICS/LABA combination containing beclomethasone dipro-
pionate and formoterol (BDP/F; Foster1; Chiesi Farmaceutici,
Parma, Italy) has been developed in a pressurised metered
dose inhaler (pMDI) using a hydrofluoralkane propellant to
deliver an extrafine formulation capable of reaching the small
airways [17]. This combination inhaler is licensed for use in
patients with asthma, as it effectively improves pulmonary
function and symptoms in subjects suffering from moderate-
to-severe disease [18], with comparable efficacy compared to
other fixed-dose ICS/LABA combinations achieved using a
lower daily dose of inhaled corticosteroid (400 mg daily) [19,
20]. This lower daily dose is possible because of the optimised
lung deposition characteristics of the extrafine formulation. A
study in COPD patients has shown that the extrafine BDP/F
and the BUD/F combinations cause similar improvements in
forced expiratory volume in 1 s (FEV1) with both combinations
being superior to formoterol alone [21]. However, neither of
the combinations showed superiority compared to formoterol
alone for the reduction of COPD exacerbations. The most likely
explanation for this finding is that the population enrolled had
a low rate of exacerbations, due in part to the study design,
which required patients to be very stable at enrolment (i.e. free
from exacerbations foro2 months before study screening and
during a 4-week run-in period) and, therefore, less likely to
exacerbate thereafter. The potentially beneficial effects of the
BDP/F extrafine combination on exacerbation rates needs to be
further investigated in patients with frequent exacerbations.
The BDP/F extrafine combination has the potential to minimise
long-term corticosteroid-related side-effects in COPD patients,
as the corticosteroid dose used is lower than other fixed-dose
ICS/LABA combinations [21]. However, it is necessary to
demonstrate that this lower corticosteroid dose reduces exacer-
bation rates. We present the design of the FORWARD clinical
trial (Foster 48-week Trial to Reduce Exacerbations in COPD),
which investigates the effect of the extrafine BDP/F combina-
tion compared to extrafine formoterol alone on exacerbation
rates in severe COPD patients with an exacerbation history. The
trial design has been optimised to measure exacerbation rates;
recruitment is in three winter waves across the globe in order to
capture the winter seasonal peak of exacerbations, and EXACT
is being used to enhance the detection of exacerbation events.
This PRO is being collected using a digital platform technology
to enhance the efficiency of data capture (HealthDiary, Inc.,
Toronto, Canada [22]); the physician will be able to monitor
EXACT scores in real time on a daily basis. The traditional
physician diagnosis of exacerbations is a primary outcome of
this trial, but the trial is also expected to provide important
information on the ability of EXACT to detect and measure
exacerbations in a large clinical trial setting.
METHODS
Study objectives
The primary objective is to investigate whether the BDP/F
combination twice daily is superior to formoterol twice daily in
patients with severe COPD in terms of: 1) the reduction of
exacerbation rates during 48 weeks of treatment; and 2) the
improvement in pulmonary function, measured by the change in
pre-dose morning FEV1 from baseline to week 12. The main
secondary objectives are to assess the efficacy of the BDP/F
combination in terms of the change from baseline in morning
pre-/post-dose lung function and the time to first COPD
exacerbation. The safety of the treatments is also evaluated in
terms of adverse events, vital signs and blood parameters. The
end-points are listed fully in table 1.
Subjects
Patients with severe COPD aged .40 yrs are being recruited. A
minimum of 1,102 patients will be randomised in order that
o952 patients complete the study (476 per treatment group)
based on an estimated drop-out rate of 13.5%. The inclusion
criteria are post-bronchodilator FEV1 30–50% of predicted value
with FEV1/forced vital capacity (FVC) ratio ,0.7, a smoking
history of o10 pack-yrs, a documented history in the patient’s
medical records of one or more exacerbation within the previous
12 months that required healthcare utilisation (hospitalisation
and/or emergency department admission) or treatment with
antibiotics and/or oral corticosteroids and the ability to use
TABLE 1 End-points of the FORWARD study
Co-primary end-points
Comparison of Foster1 versus formoterol alone in terms of:
COPD exacerbation rate
Change in pre-dose morning FEV1 from baseline to week 12
Secondary end-points
Change from baseline in morning pre-dose and 2-h post-dose FEV1 and
FVC at all clinic visits
Change from baseline to the average pre-dose FEV1 over the treatment period
Change from pre-dose to 2-h post-dose FEV1 and FVC at all clinic visits
Pre-dose and 2-h post-dose FEV1/FVC
Time to first COPD exacerbation
Change from baseline to the end of treatment in the SGRQ total and
component scores
Change from baseline to the entire treatment period and to each inter-visit
period in the percentage of rescue use-free days and in the average use
of rescue medication (number of puffs per day)
Exploratory end-points
Change from baseline to the entire randomised treatment period and to
each inter-visit period in the EXACT-PRO total score and subscale scores
Safety end-points
Adverse events
Adverse drug reactions
Vital signs
Haematology and blood biochemistry, including potassium and glucose
FORWARD: Foster 48-week Trial to Reduce Exacerbations in COPD; COPD:
chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s;
FVC: forced vital capacity; SGRQ: St George’s Respiratory Questionnaire;
EXACT: Exacerbations of Chronic Pulmonary Disease Tool; PRO: patient-
recorded outcome.
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EXACT questionnaire loaded onto a BlackBerry1 (Research In
Motion, Waterloo, Canada) digital platform. Exclusion criteria are
a previous diagnosis of asthma, allergic rhinitis or atopic diseases
such as eczema, obstructive symptoms in childhood, unstable
concurrent diseases, significant hepatic or renal impairment,
significant concurrent pulmonary diseases such as tuberculosis or
lung cancer, serum potassium levels ,3.5 mmol?L-1, a history of
antibiotic and/or oral corticosteroid treatment for an exacerba-
tion of COPD in the 4 weeks before screening and during the run-
in, oxygen therapy for .12 h?day-1 or the use of mechanical
noninvasive ventilation. Additionally, the following patients are
excluded: those treated with depot corticosteroids or long-acting
antihistamines in the 2 months preceding the screening visit and
those treated with b-blockers in the week preceding the screening
visit. Patients treated with tiotropium or theophylline are allowed
to enter the study and continue these medications, provided that
there are no changes in the dose, schedule or formulation of these
drugs within 3 and 2 months, respectively, before the screening
visit. All patients provide written informed consent, and the
study is ethically approved. The study is registered at clinical-
trials.gov (NCT00929851).
Recruitment is being performed in three waves capturing the
winter exacerbation season; the first wave was held in Western
Europe (Austria, Czech Republic, Germany and the UK) starting
in October 2009. The second wave recruited patients in the
southern hemisphere (Argentina, Australia, Chile, New Zealand
and South Africa) starting in April 2010. The third wave was
held in Europe starting in October 2010 (Bulgaria, Czech
Republic, France, Germany, Hungary, Italy, the Netherlands,
Poland, Romania, Spain, Turkey and the UK).
Study design
This is a 48-week, double-blind, randomised, multinational,
multicentre, two-arm, parallel-group clinical trial of a fixed
combination of BDP/F administered via pMDI (Foster1) versus
formoterol alone (Atimos1; Chiesi Farmaceutici). The study
design is shown in figure 1, with patients undergoing eight clinic
visits. At visit 0 (V0), consent is gained and the study visits
explained. At V1 (screening visit), the eligibility of patients is
assessed, including spirometry before and after the administra-
tion of 400 mg inhaled salbutamol. There follows a 2-week run-in
period when all patients receive formoterol 12 mg twice a day
plus salbutamol as required. The randomisation visit (V2) is
followed by a 48-week treatment period with patients randomly
allocated to receive either BDP/F combination or formoterol
alone. Patients take either two inhalations of BDP/F 100/6 mg
twice per day, or one inhalation of formoterol 12 mg twice per
day. The double-blind design is ensured by the addition, in
the formoterol arm, of a placebo canister following the same
administration pattern as formoterol, i.e. one inhalation twice per
day. Salbutamol is used as a rescue medication throughout the
study. Patients taking tiotropium are required to stop this
medication for 72 h before each visit to the clinic (V1–V7) and are
then allowed to restart after the visit.
Clinic visits occur at 4, 12, 24, 36 and 48 weeks after randomisa-
tion. At these visits, FEV1 and FVC (pre-dose and 2 h post-dose)
and vital signs are measured. COPD exacerbations and adverse
events are recorded throughout the study. The St George’s
Respiratory Questionnaire (SGRQ) is administered at V2 and V7,
and the evaluation of haematology and blood biochemistry and
ECG are performed at V1 and V7. In case of early discontinua-
tion, V7 assessments should be performed. The use of rescue
medication and the EXACT scores are recorded daily by the
patient using the BlackBerry1 and transmitted daily as encrypted
data to centralised database servers.
Measurement of exacerbations
A COPD exacerbation is defined as a sustained worsening of the
patient’s condition (dyspnoea, cough and/or sputum produc-
tion/purulence) from the stable state and beyond normal day-
to-day variations that is acute in onset and requires unsched-
uled medical intervention, leading to prescriptions of systemic
corticosteroids and/or antibiotics or the need for a visit to an
emergency department or hospitalisation [23]. The physician-
diagnosed COPD exacerbations that fit the above criteria,
corresponding to HealthCare Resource Utilisation (HCRU)
exacerbations, will be used for the analysis of the exacerbation
rate as the co-primary end-point.
EXACT assesses breathlessness, cough and sputum, chest symp-
toms, and quality of life using a 14-item questionnaire with a total
score ranging from 0 to 100. In the FORWARD study, the baseline
EXACT total score for each patient will be calculated based on the
first 14 days’ scores after the screening visit. Each investigator
can review individual EXACT scores via the web. During the
treatment period, a change in the total score of .12 compared
with baseline on two consecutive days automatically triggers an
alert to the investigator, through the digital platform, that a
significant change in symptoms has occurred. Simultaneously,
the BlackBerry1 also delivers the individualised message (‘‘Please
remember to call your doctor if your symptoms worsen’’) when
this worsening of symptoms has occurred. This message is also
delivered to the patient at regular intervals during the study.
Upon the 12-point increase alert, the investigator then checks the
patient’s clinical status by a telephone call, and makes the decision
whether to arrange a clinic visit to further assess the symptoms.
The EXACT score will be used to assess exacerbation patterns in
the study as an exploratory outcome; the co-primary end-point
of HCRU exacerbations will be compared to the exploratory
outcome of EXACT-detected events.
Week -2 Day 1 Week 4 Week 12 Week 24 Week 36 Week 48
Physician-diagnosed COPD exacerbation: record and follow-up
Daily electronic transmission of EXACT-PRO score
F 12 µg b.i.d.
Run-in F
V1 V2 V3 V4 V5 V6 V7
BDP/F
Randomisation
2 inhalations 100/6 µg b.i.d.
1 inhalation 12 µg b.i.d.
FIGURE 1. The double-blind parallel group randomised study design is
shown. At screening, each patient receives a Blackberry1 (Research In Motion,
Waterloo, Canada), configured to receive the Exacerbations of Chronic Pulmonary
Disease Tool (EXACT) means of collecting patient-reported outcome (PRO)
questionnaire daily. During the 48 weeks of the randomised period, healthcare
utilisations due to exacerbations of chronic obstructive pulmonary disease (COPD)
are recorded. BDP: beclomethasone dipropionate; F: formoterol; V: visit.
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Statistics
The sample size has been calculated to demonstrate the super-
iority of BDP/F compared to formoterol for COPD exacerbation
rates and change in pre-dose morning FEV1 from baseline to
week 12. With 551 randomised patients per group, assuming
0.64 exacerbations per patient per year in the BDP/F group and
0.8 in the formoterol group, an exponential distribution of
dropouts with a cumulative percentage of 13.5% at the end of the
study, an overdispersion factor of 10% (i.e. variance of number of
exacerbations51.16mean number of exacerbations) and a two-
sided significance level of 0.05, simulations suggest that the
power using Poisson regression will be 82.6%. With 530
evaluable patients at week 12 in each group, the study will have
80% power to detect a mean difference of 50 mL in change in pre-
dose morning FEV1, assuming a standard deviation of 290 mL,
using an unpaired t-test with two-sided significance level of 0.05.
The difference of 50 mL was chosen based on previous long-term
clinical trials showing that ICS/LABA combinations show this
level of superiority over LABA alone, and this is associated with
differences in health status and exacerbation rates [14, 15, 16, 21].
Further statistical analysis details are in the online supplemen-
tary material.
The frequency distribution of adverse events and adverse drug
reactions will be presented for each treatment group. The mean
and 95% confidence intervals for the changes from baseline in
vital signs will be calculated within each treatment group. Shift
tables from baseline to the end of treatment, with regard to
normal ranges, will be provided for the laboratory parameters
for each treatment group.
DISCUSSION
The FORWARD study will evaluate the potential benefits of
the extrafine BDP/F combination inhaler compared to extra-
fine formoterol on exacerbation rate and lung function in
COPD patients. The study design allows the effects of the ICS
component of the extrafine BDP/F combination to be
determined in the specific subgroup of patients who are at
most risk of future exacerbations. The recruitment approach
employed in the study was specifically designed to enrich the
patient population by ensuring the recruitment of patients
prone to exacerbations. The frequency and severity of COPD
exacerbations is worse during the winter season [4, 5] and the
study design is optimised to capture such seasonal events by
randomising patients immediately before the winter peak of
exacerbations. Furthermore, the use of EXACT scores trans-
mitted digitally on a daily basis may provide a sensitive way to
detect and monitor exacerbation events, and thus enable
differences between the study treatments to be accurately
determined.
The co-primary end-points of the FORWARD study are the
reduction of exacerbation rate during 48 weeks of treatment and
the improvement in FEV1 from baseline to week 12. Exacerbation
rate and lung function were investigated in the previous study
comparing the effects of extrafine BDP/F, BUD/F and formoterol
alone in COPD patients [21]. It was observed that both
combination therapies were superior to formoterol in terms of
FEV1 improvement, and a similar result is expected in the
FORWARD study. The lack of superiority over formoterol of both
extrafine BDP/F and BUD/F in terms of exacerbation rate was
unexpected and in contrast with results from previous studies
showing superiority of BUD/F and FP/S over LABA alone [14–
16]. The low exacerbation rate detected in the previous study
with extrafine BDP/F (,0.42 per patient-year) as compared to
previous studies (.0.8 per patient-year in TORCH (Towards a
Revolution in COPD Health) [14] and f1.6 per patient-year in
INSPIRE (Investigating New Standards for Prophylaxis in
Reducing Exacerbations) [24]) might have masked the beneficial
effect of extrafine BDP/F on reduction of exacerbations.
FORWARD has therefore been designed to recruit a COPD
population with a higher exacerbation frequency in order to
evaluate the efficacy of BDP/F combination on this end-point.
The daily EXACT score transmission enhances the contact
between patients and physicians. The automatic alert to the
physician, whenever the score of a specific patient increases by
o12 points for two consecutive days, may increase the number
of physician-diagnosed exacerbations requiring HCRU. EXACT
may therefore reduce the proportion of unreported exacerbation
events and at the same time increase HCRU.
In addition to studying the rate of exacerbations requiring
additional treatment, the FORWARD study will include a series
of exploratory analyses on symptom patterns and exacerbations
evaluated using EXACT [9, 10]. This may include, but is not
limited to, frequency, severity and duration of exacerbations. The
EXACT questionnaire seems able to consistently quantify the
symptoms associated with an exacerbation [11] and may provide
a useful tool for quantifying exacerbations in clinical trials.
In our study, all patients fill out their EXACT questionnaire on
a mobile device and it will be possible to compare this symptom-
based approach with the event-based calculation of exacerbation
rates. The daily questionnaire, duly completed, is transmitted,
anonymously and encrypted, to the digital platform developed
specifically for the FORWARD study. The study design is unique
in providing the investigator with daily information of the
patients’ clinical status from the reports of the EXACT focused
on COPD exacerbations. This is an essential part of the study
design, promoting early detection of events to allow an
immediate response to the patients’ change in symptoms.
There is a known under-reporting of exacerbations that will
lead to conservative estimates of exacerbation rate when the
more conventional definition of exacerbations based on addi-
tional treatments is used [8]. Using EXACT can tell us more
about the degree of under-reporting as well as the distribution of
this phenomenon in a clinical trial setting. Also, treatment with
inhaled corticosteroids not only reduces exacerbation rates, since
they have also been shown to reduce the severity of exacerba-
tions [25]. Using EXACT scores in the FORWARD study may
enable us to compare exacerbation severity by the assessment of
symptoms in the two treatment groups. It has recently been
shown that COPD exacerbations follow distinct patterns of onset
and recovery [26], and EXACT has the potential to accurately
measure the whether the randomised treatments change such
patterns in this clinical trial.
The early detection of a change in symptoms due to the
information provided by EXACT should occur equally in both
treatment arms, so we do not expect that the use of EXACT will
cause a bias towards increased detection of exacerbation events in
one treatment arm only. It could be argued that the administra-
tion of EXACT through the BlackBerry1 device will be difficult
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for certain subjects, such as those who are not competent with
the use of mobile telephones. However, the operation of the
BlackBerry1 has been simplified to administer EXACT, and this
technique has been developed and validated in COPD patients
[9–11], so we do not expect this to be a major issue.
SGRQ scores and rescue medication usage will be measured as
secondary end-points to assess quality of life and breath-
lessness, respectively. These measurements are commonly
used in COPD clinical trials [14–16, 24]. We have limited the
number of other secondary end-point measurements per-
formed in order to focus on achieving quality in the primary
end-point measurements, and also for practical reasons to not
overload patients with clinical procedures.
Previous studies of ICS/LABA combinations in COPD have
either not permitted the widely prescribed long-acting anti-
cholinergic tiotropium to be used, or were performed before
tiotropium was licensed for use [14–16]. We have allowed
patients who are taking tiotropium to continue with this
medication during the FORWARD study, as it allows the
comparison of extrafine BDP/F to extrafine formoterol to be
performed with the patients taking their normal and recom-
mended COPD medications. This is different to previous ICS/
LABA studies in COPD [14, 21] and, arguably, is a more ‘‘real-
life’’ study design. Furthermore, there are ethical issues in asking
severe COPD patients to withhold an effective medication over a
year for research purposes and to be treated with formoterol only.
Tiotropium will not be used for 72 h prior to the measurement of
pulmonary function, so that the potential difference between the
study treatments can be evaluated without the bronchodilator
effect of concurrent tiotropium administration which may cause
difficulty in interpretation.
The combination inhalers containing FP/S (Seretide1;
GlaxoSmithKline, Uxbridge, UK) and BUD/F (Symbicort1;
AstraZeneca, London, UK) are already widely used for the
treatment of COPD. The key COPD studies with these combina-
tions have been performed with dry powder inhalers (Diskus1
(GlaxoSmithKline) and the Turbohaler1 (AstraZeneca) respec-
tively) [14–16]. Many patients prefer using pMDI devices;
extrafine BDP/F pMDI therefore offers an alternative device for
such patients. Furthermore, the pMDI extrafine formulation
enhances deposition in small airways, which is an important site
of airway inflammation in COPD patients [27]. The delivery of
treatment to the small airways may be important for reducing the
progression of inflammation and obstruction at this site. Indeed,
it has been demonstrated that BDP/F causes a greater improve-
ment in FVC compared to either BUD/F or formoterol in patients
with COPD, indicating an effective reduction of air trapping
associated with small airway patency [21]. Moreover, the
extrafine formulation of Foster1 offers the benefit of a reduced
efficacious dose of inhaled corticosteroid (400 mg daily) com-
pared to other fixed-dose combinations of ICS and LABAs. This
lower daily dose may reduce the rate of ICS side-effects,
including the increased frequency of pneumonia observed in
TORCH [14].
In conclusion, the FORWARD study will evaluate the effect of the
ICS component of the extrafine BDP/F combination on exacer-
bation rate and pulmonary function in severe COPD patients
with a history of frequent exacerbations. The FORWARD study
will also provide data on the use of EXACT in a large clinical trial.
Changes in EXACT scores during physician-diagnosed exacer-
bations will be explored, and the ability of quantitative scores
from the EXACT to add additional information on impact of
treatment on features of exacerbations will be explored. The use
of EXACT scores, coupled with the capture of winter exacerba-
tion peaks across the globe, may provide a sensitive study design
for investigating the effects of pharmacotherapies on exacerba-
tion rates in COPD patients.
SUPPORT STATEMENT
This study was supported by Chiesi. Foster1 and Atimos1 were
donated by Chiesi and BlackBerrys were leased by Chiesi.
CLINICAL TRIAL
This study is registered at clinicaltrials.gov with identifier number
NCT00929851.
STATEMENT OF INTEREST
Statements of interest for all authors and for the study itself can be
found at www.erj.ersjournals.com/site/misc/statements.xhtml
REFERENCES
1 Wedzicha JA, Seemungal TA. COPD exacerbations: defining their
cause and prevention. Lancet 2007; 370: 786–796.
2 Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerba-
tion on quality of life in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422.
3 Soler-Catalun˜a JJ, Martı´nez-Garcia MA, Roma´n Sa´nchez P, et al.
Severe acute exacerbations and mortality in patients with chronic
obstructive pulmonary disease. Thorax 2005; 60: 925–931.
4 Jenkins CR, Celli B, Anderson JA, et al. Seasonality and
determinants of moderate and severe COPD exacerbations in the
TORCH study. Eur Respir J 2012; 39: 38–45.
5 Donaldson GC, Goldring JJ, Wedzicha JA. Influence of season on
exacerbation characteristics in patients with COPD. Chest 2012;
141: 94–100.
6 Greenberg SB, Allen MJ, Wilson J, et al. Respiratory viral infections
in adults with and without chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2000; 162: 167–173.
7 Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation
in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:
1128–1138.
8 Langsetmo L, Platt RW, Ernst P, et al. Underreporting exacerbation
of chronic obstructive pulmonary disease in a longitudinal cohort.
Am J Respir Crit Care Med 2008; 177: 396–401.
9 Leidy NK, Wilcox TK, Jones PW, et al. Development of the
EXAcerbations of Chronic Obstructive Pulmonary Disease Tool
(EXACT): a patient-reported outcome (PRO) measure. Value Health
2010; 13: 965–975.
10 Jones PW, Chen WH, Wilcox TK, et al. Characterizing and
quantifying the symptomatic features of COPD exacerbations.
Chest 2011; 139: 1388–1394.
11 Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement
of chronic obstructive pulmonary disease exacerbations: reliability
and validity of a patient-reported diary. Am J Respir Crit Care Med
2011; 183: 323–329.
12 Global Initiative for Chronic Obstructive Lung Disease. Global
Strategy for Diagnosis, Management, and Prevention of COPD.
www.goldcopd.org/guidelines-global-strategy-for-diagnosis-mana
gement.html.
13 Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid
receptor nuclear translocation in airway cells after inhaled
combination therapy. Am J Respir Crit Care Med 2005; 172: 704–712.
LAUNCHING NEW STUDIES: COPD D. SINGH ET AL.
16 VOLUME 41 NUMBER 1 EUROPEAN RESPIRATORY JOURNAL
14 Calverley PM, Anderson JA, Celli B, et al. Salmeterol and
fluticasone propionate and survival in chronic obstructive
pulmonary disease. N Engl J Med 2007; 356: 775–789.
15 Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of
budesonide/formoterol in the management of chronic obstructive
pulmonary disease. Eur Respir J 2003; 21: 74–81.
16 Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy
with budesonide and formoterol in chronic obstructive pulmonary
disease. Eur Respir J 2003; 22: 912–919.
17 Acerbi D, Brambilla G, Kottakis I. Advances in asthma and COPD
management: delivering CFC-free inhaled therapy using Modulite
technology. Pulm Pharmacol Ther 2007; 20: 290–303.
18 Huchon G, Magnussen H, Chuchalin A, et al. Lung function and
asthma control with beclomethasone and formoterol in a single
inhaler. Respir Med 2009; 103: 41–49.
19 Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/formoterol
vs fluticasone/salmeterol inhaled combination in moderate to
severe asthma. Allergy 2007; 62: 1182–1188.
20 Papi A, Paggiaro PL, Nicolini G, et al. Beclomethasone/formoterol
versus budesonide/formoterol combination therapy in asthma. Eur
Respir J 2007; 29: 682–689.
21 Calverley PMA, Kuna P, Monso E, et al. Beclomethasone/formoterol
in the management of COPD: a randomised controlled trial. Respir
Med 2010; 104: 1858–1868.
22 HealthDiary. Overview: the HealthDiary platform. www.healthdiary.
ca/overview.aspx.
23 Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus
salmeterol for the prevention of exacerbations of COPD. N Engl J
Med 2011; 364: 1093–1103.
24 Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention
of chronic obstructive pulmonary disease exacerbations by
salmeterol/fluticasone propionate or tiotropium bromide. Am J
Respir Crit Care Med 2008; 177: 19–26.
25 Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised
placebo-controlled trial of inhaled fluticasone propionate in
patients with chronic obstructive pulmonary disease. Lancet
1998; 351: 773–780.
26 Aaron SD, Donaldson GC, Whitmore GA, et al. Time course and
pattern of COPD exacerbation onset. Thorax 2012; 67: 238–243.
27 Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway
obstruction in chronic obstructive pulmonary disease. N Eng J Med
2004; 350: 2645–2652.
D. SINGH ET AL. LAUNCHING NEW STUDIES: COPD
EUROPEAN RESPIRATORY JOURNAL VOLUME 41 NUMBER 1 17
